Deep IM Inj in deltoid for older childn & in anterolateral thigh for infants. Primary vaccination 3 doses in 1st yr of life starting from age 2 mth w/ at least 1-mth interval between subsequent doses. When primary course is completed before age 6 mth, booster dose can be given in the 2nd yr of life w/ 6-mth interval after completion of primary vaccination.
Known or previous hypersensitivity. Encephalopathy of unknown aetiology occurring w/in 7 days following previous vaccination w/ pertussis-containing vaccine.
Hypersensitivity to neomycin & polymyxin. Postpone vaccination in patients suffering from acute severe febrile illness. Not to be administered as IV. History of febrile convulsions; family history of convulsions, sudden infant death syndrome & adverse event following DPT vaccination. Patients w/ thrombocytopenia or bleeding disorder. Immunosuppressed patients. Syncope. Perform review of medical history & clinical exam before vaccination. Carefully consider giving subsequent doses of pertussis-containing vaccines to patients w/ rectal temp ≥40°C, collapse or shock-like state (hypotonic-hyporesponsive episode), persistent, inconsolable crying lasting ≥3 hr w/in 48 hr of vaccination; convulsions w/ or w/o fever w/in 3 days of vaccination. Defer pertussis immunization in childn w/ progressive neurological disorders including infantile spasms, uncontrolled epilepsy, progressive encephalopathy. Pregnancy & lactation. Potential risk of apnoea; consider need for resp monitoring for 48-72 hr in very premature infant (≤28 wk of gestation) & those w/ history of resp immaturity.
Loss of appetite; restlessness, abnormal crying, irritability; headache (6-13 yr), somnolence; inj site reactions (eg, pain, redness, local swelling at inj site (≤50 mm), fever (≥38°C). Nausea, vomiting, diarrhoea; local swelling at inj site (>50 mm), asthenia, malaise, inj site reactions including induration.
Sign Out
